Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
6.07
-0.21 (-3.42%)
At close: Jul 25, 2025, 4:00 PM
6.06
-0.01 (-0.08%)
After-hours: Jul 25, 2025, 4:20 PM EDT
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Amicus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $26.89, which forecasts a 343.36% increase in the stock price over the next year. The lowest target is $9 and the highest is $108.
Price Target: $26.89 (+343.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 2 | 2 | 2 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $102 → $108 | Hold → Buy | Upgrades | $102 → $108 | +1,680.71% | Jul 17, 2025 |
| UBS | UBS | Strong Buy Maintains $21 → $22 | Strong Buy | Maintains | $21 → $22 | +262.74% | May 2, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $12 → $9 | Hold | Maintains | $12 → $9 | +48.39% | May 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +180.30% | Feb 20, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 20, 2025 |
Financial Forecast
Revenue This Year
633.27M
from 528.30M
Increased by 19.87%
Revenue Next Year
779.87M
from 633.27M
Increased by 23.15%
EPS This Year
-0.09
from -0.18
EPS Next Year
0.26
from -0.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 657.2M | 874.2M | 1.1B | ||
| Avg | 633.3M | 779.9M | 950.3M | ||
| Low | 604.7M | 712.9M | 839.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 24.4% | 38.1% | 43.6% | ||
| Avg | 19.9% | 23.1% | 21.9% | ||
| Low | 14.5% | 12.6% | 7.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.03 | 0.44 | 0.86 | ||
| Avg | -0.09 | 0.26 | 0.68 | ||
| Low | -0.15 | 0.13 | 0.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 227.5% | ||
| Avg | - | - | 157.3% | ||
| Low | - | - | 93.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.